Insert logo of [authorising body](https://www.nice.org.uk/guidance/mpg2/chapter/Recommendations#terms-used-in-the-guideline)

|  |
| --- |
| This Patient Group Direction (PGD) must only be used by registered healthcare professionals who have been named and authorised by their organisation to practice under it. The most recent and in date final signed version of the PGD should be used. |

**PATIENT GROUP DIRECTION (PGD)**

**Insertion of etonogestrel (e.g. Nexplanon®) 68mg subdermal implant for contraception in location/service/organisation**

Version Number 2.1

|  |
| --- |
| **Change History** |
| **Version and Date** | **Change details** |
| Version 1October 2020 | New template |
| Version 1.1November 2020  | Addition of acute porphyria to exclusion criteria  |
| Version 1.2June 2021 | Special considerations – addition of the following wording:*Other possible complications of insertion and removal procedures include local reaction, nerve damage, and deep or intramuscular insertion.* |
| Version 2.0May 2023 | Updated template (no clinical changes to expired V1). Updated adverse effects and references. Removed statement relating to Covid-19. Minor changes to some wording and formatting. Aligned content with other PGDs for same or associated medicine / group. Updated PGD development group members. |
| Version 2.1April 2024 | Added note re low risk of breast cancer. Updated references. Updated SLWG. |

Each organisation using this PGD must ensure that it is formally signed by a senior pharmacist, a senior doctor and any other professional group representatives involved in its review and that it is reviewed in line with the organisations’ PGD governance system. The organisation’s governance lead must sign to authorise the PGD on behalf of the authorising organisation to ensure that this document meets legal requirements for a PGD.

**PGD DEVELOPMENT GROUP**

|  |  |
| --- | --- |
| Date PGD template comes into effect:  | September 2023 |
| Review date: | March 2026 |
| Expiry date:  | August 2026  |

This PGD template has been peer reviewed by the Reproductive Health PGDs Short Life Working Group in accordance with their Terms of Reference. It has been approved by the Faculty for Sexual and Reproductive Health (FSRH) in April 2023. Note the working group and approving organisation(s) agreement to the content only applies to the national template and does not extend to any local adaptations made to any of the content which are solely the responsibility of the organisation authorising the PGD. The most up to date version of the template is available here:

<https://www.sps.nhs.uk/home/guidance/patient-group-directions/templates/>

**This section MUST REMAIN when a PGD is adopted by an organisation.**

|  |  |
| --- | --- |
| **Name** | **Designation** |
| Dr Cindy Farmer | Vice President, Professional Learning and Development FSRH |
| Michelle Jenkins | Advanced Nurse Practitioner FSRH |
| Vicky Garner | Consultant Midwife British Pregnancy Advisory Service (BPAS) |
| Sim Sesane  | CASH Nurse Consultant MSI Reproductive Choices |
| Kate Devonport | National Unplanned Pregnancy Association (NUPAS) |
| Chetna Parmar | Pharmacist adviser Umbrella  |
| Heather Randle | Royal College of Nursing (RCN) |
| Carmel Lloyd | Royal College of Midwives (RCM) |
| Clare Livingstone | Royal College of Midwives (RCM) |
| Kirsty Armstrong  | National Pharmacy Integration Lead, NHS England |
| Dipti Patel | Local authority pharmacist  |
| Emma Anderson | Centre for Postgraduate Pharmacy Education (CPPE) |
| Alison Crompton | Community pharmacist |
| Lisa Knight | Community Health Services pharmacist  |
| Bola Sotubo | ICB pharmacist |
| Tracy Rogers | Director, Medicines Use and Safety, Specialist Pharmacy Service  |
| Sandra Wolper  | Associate Director Specialist Pharmacy Service |
| Jo Jenkins  | Lead Pharmacist PGDs and Medicine Mechanisms, Medicines Use and Safety, Specialist Pharmacy Service |
| Rosie Furner (Working Group Co-ordinator) | Governance Pharmacist, Medicines Use and Safety, Specialist Pharmacy Service |

**The PGD template is not legally valid until it has had the relevant organisational approval - see below.**

**ORGANISATIONAL AUTHORISATIONS AND OTHER LEGAL REQUIREMENTS**

**This page may be deleted if replaced with a format agreed according to local PGD policy with relevant approvals and authorisation.**

The PGD is not legally valid until it has had the relevant organisational authorisations.

To ensure compliance with the law, organisations must add local authorisation details i.e. clinical authorisations and the person signing on behalf of the authorising organisation. You may either complete details below or delete and use a format agreed according to local PGD policy which complies with PGD legislation and [NICE MPG2 PGD 2017](https://www.nice.org.uk/Guidance/MPG2).

|  |  |  |  |
| --- | --- | --- | --- |
| **Name**  | **Job title and organisation**  | **Signature** | **Date** |
| **Senior doctor**  |  |  |  |
| **Senior pharmacist** |  |  |  |
| **Senior representative of professional group using the PGD**  |  |  |  |
| **Person signing on behalf of** [**authorising body**](https://www.legislation.gov.uk/uksi/2012/1916/schedule/16) |  |  |  |

It is the responsibility of the provider organisation to ensure that all legal and governance requirements for using the PGD are met.

To meet legal requirements, authorising organisations must add an Individual Practitioner Authorisation sheet or List of Authorised Practitioners. This varies according to local policy and how the service is managed but this should be a signature list or an individual agreement.

PGDs do not remove inherent professional obligations or accountability. It is the responsibility of each professional to practice only within the bounds of their own competence and in accordance with their own Code of Professional Conduct. Individual practitioners must declare that they have read and understood the Patient Group Direction and agree to supply/administer medication(s) listed only in accordance with the PGD.

**ORGANISATIONS MAY ALSO ADD:**

* Local training and competency assessment documentation
* Other supporting local guidance or information
* Links to local PGD Policy and other supporting guidance
* Audit requirements

Any reference to a Trust protocol (either clinical to be followed as part of the administration of a medication with the PGD or for any other purpose) must be referenced and hyperlinked to ensure the practitioner acting under the PGD has direct access to the protocol for reference.

1. **Characteristics of Staff**

|  |  |
| --- | --- |
| **Qualifications and professional registration** | Current contract of employment within a Local Authority or NHS commissioned service or an NHS Trust/organisation.Registered healthcare professional listed in the legislation as able to practice under Patient Group Directions.  |
| **Initial training** | The registered healthcare professional authorised to operate under this PGD must have undertaken appropriate education and training and successfully completed the competencies to undertake clinical assessment of patients ensuring safe provision of the medicines listed in accordance with local policy. Recommended requirement for training would be successful completion of a relevant general contraception module/course accredited or endorsed by the FSRH, CPPE or a university or as advised in the RCN training directory. In addition, completion of the FSRH Letter of competence (LOC) in Subdermal implants (LOC SDI-IR/LOC SDI-IO) or locally agreed additional training and been assessed as competent at the insertion and removal, if applicable, of the subdermal implant. Individual has undertaken appropriate training for working under PGDs for the supply and administration of medicines. Recommended training - [eLfH PGD elearning programme](https://www.e-lfh.org.uk/programmes/patient-group-directions/) Individuals working under this PGD will be required to administer local anaesthesia in line with local protocols/PGDs.The healthcare professional must keep up to date with current FSRH guidance on the insertion site, including any relevant MHRA Drug Safety Updates.The healthcare professional has completed training and is up to date with service requirements/specification for safeguarding children and vulnerable adults. (amend as per local policy).The healthcare professional must ensure that they have an up to date certificate for Basic Life Support (BLS) and anaphylaxis as required by the employing Trust/organisation |
| **Competency assessment** | * Individuals operating under this PGD must be assessed as competent (see Appendix A) or complete a self-declaration of competence for contraception supply.
* Staff operating under this PGD are encouraged to review their competency using the [NICE Competency Framework for health professionals using patient group directions](https://www.nice.org.uk/guidance/mpg2/resources)
 |

|  |  |
| --- | --- |
| **Ongoing training and competency** | * Individuals operating under this PGD are personally responsible for ensuring they remain up to date with the use of all medicines and guidance included in the PGD - if any training needs are identified these should be addressed and further training provided as required.
* Organisational PGD and/or medication training as required by employing Trust/organisation.
 |
| The decision to administer any medication rests with the individual registered health professional who must abide by the PGD and any associated organisational policies.  |

**2. Clinical condition or situation to which this PGD applies**

|  |  |
| --- | --- |
| **Clinical condition or situation to which this PGD applies** | Contraception  |
| **Criteria for inclusion** | * Any individual from menarche to 55 years presenting for contraception and who has no contraindications
* Where appropriate individuals requiring insertion of this subdermal contraceptive implant should also meet the inclusion criteria of the lidocaine 1% PGD template (see PGD for lidocaine)
* Consent given
 |
| **Criteria for exclusion** | * Consent not given.
* Individuals under 16 years of age and assessed as not competent using Fraser Guidelines.
* Individuals 16 years of age and over and assessed as lacking capacity to consent.
* Known hypersensitivity to the active ingredient or to any constituent of the product - see [Summary of Product Characteristics](https://www.medicines.org.uk/emc) (SPC)
* Established pregnancy. Note-risk of pregnancy with a negative pregnancy test is not an absolute exclusion.
* Unexplained vaginal bleeding (suspicious of serious condition) before evaluation
* Acute porphyria

**Cardiovascular Disease*** Current or past history of ischaemic heart disease, vascular disease, stroke or transient ischaemic first attack only if these events first occurred during use of the etonogestrel implant.

**Cancers** * Current or past history of breast cancer.
* Benign liver tumour (hepatocellular adenoma).

**Gastro-intestinal conditions*** Severe decompensated cirrhosis.
* Malignant liver tumour (hepatocellular carcinoma).

**Interacting medicines*** Individuals using enzyme-inducing drugs/herbal products or within 28 days of stopping them. See Interactions section.
 |
| **Cautions including any relevant action to be taken** | * If the individual is less than 16 years of age an assessment based on Fraser guidelines must be made and documented.
* If the individual is less than 13 years of age the healthcare professional should speak to local safeguarding lead and follow the local safeguarding policy.
* If the individual is taking any anticoagulant therapy, an experienced clinician should perform the procedure due to the risk of bleeding and a pressure bandage should be applied after insertion. See [Management of women taking anticoagulants or antiplatelet medications who request intrauterine contraception or subdermal implants for information about timing the insertion in relation to the anticoagulant dose](https://www.fsrh.org/Public/Documents/fsrh-guidance-fsrh-guidance-management-of-women-taking-anticoagulants.aspx?WebsiteKey=f858b086-d221-4a83-9688-824162920b1b)
* Discuss with appropriate medical/independent non-medical prescriber any medical condition or medication of which the healthcare professional is unsure or uncertain.
 |
| **Action to be taken if the individual is excluded or declines treatment**  | * Explain the reasons for exclusion to the individual and document in the consultation record.
* Record reason for decline in the consultation record.
* Where required refer the individual to a suitable health service provider if appropriate and/or provide them with information about further options.
 |

**3. Description of treatment**

|  |  |
| --- | --- |
| **Name, strength & formulation of drug** | Etonogestrel 68 mg subdermal implant |
| **Legal category** | POM |
| **Route of administration** | Superficial subdermal implant inserted, preferably into non-dominant arm, under aseptic conditions following administration of local anaesthetic, where appropriate (see PGD for lidocaine 1% injection). Manufacturer (SPC) and current MHRA guidance must be followed. |
| **Off label use** | Best practice advice is given by the FSRH and is used for guidance in this PGD and may vary from the Summary of Product Characteristics (SPC).This PGD includes the following unlicensed use(s):* Insertion in individuals over 40 years of age
* Insertion in individuals under 18 years of age
* Active venous thromboembolic disorder
* The implant may be inserted or reinserted at any time as a quick start method if it is reasonably certain that the individual is not pregnant. Additional contraception is then required for 7 days after insertion.
* The implant may be inserted immediately post-partum and after 2nd trimester abortion or miscarriage.
* The implant may be inserted at any time after mifepristone administration at medical abortion or at any stage in a surgical abortion process.

Medicines should be stored according to the conditions detailed in the Storage section below. In the event of an inadvertent or unavoidable deviation of these conditions the local pharmacy or Medicines Management team must be consulted. Where medicines have been assessed by pharmacy/Medicines Management in accordance with national or specific product recommendations as appropriate for continued use this would constitute off-label administration under this PGD. The responsibility for the decision to release the affected medicines for use lies with pharmacy/Medicines Management. Where a medicine is recommended off-label consider, as part of the consent process, informing the individual that the medicine is being offered in accordance with national guidance but that this is outside the product licence. |
| **Dose and frequency of administration** | * Insert or change implant every 3 years. Implants should be removed once expired and/ or prior to inserting a new implant.
* Insert between day 1-5 of the menstrual cycle with no need for additional precautions
* The implant may be inserted or reinserted at any time as quick start if it is reasonably certain that the individual is not pregnant. Additional contraception is then required for 7 days after insertion
* If the individual has an implant in situ which has been in place for under 3 years the implant can be removed and replaced immediately.
* If the individual has an implant in situ which has been in place for over 3 but less than 4 years the implant can be removed and replaced immediately. A pregnancy test should be performed and if negative replace the implant and advise additional contraception for 7 days after insertion with a repeat pregnancy test after 3 weeks.
* If the individual has an implant in situ which has been in place for over 4 years the implant can be removed and replaced immediately. A pregnancy test should be performed and if negative replace the implant and advise additional contraception for 7 days after insertion with a repeat pregnancy test after 3 weeks.
* If inserting the implant after levonorgestrel emergency contraception, a barrier contraception is required for 7 days.
* After the use of ulipristal acetate emergency contraception the implant should not be inserted for five days. A barrier contraceptive should then be used for a further 7 days.
* A pregnancy test is advised three weeks after any oral emergency contraception - see [FSRH guidance](https://www.fsrh.org/Public/Documents/ceu-clinical-guidance-emergency-contraception-march-2017.aspx)
* For guidance on changing from one contraceptive method to another, and when to start after an abortion, miscarriage and post-partum refer to [FSRH guidelines](https://www.fsrh.org/Public/Standards-and-Guidance/Contraception-After-Pregnancy.aspx).
 |
| **Duration of treatment** | * Each implant is effective for three years.
* Repeat implants can be inserted for as long as the individual requires the implant and has no contraindications to its use.
 |
| **Special considerations** | There have been rare reports of local and distant intravascular migration of Nexplanon® implants. An implant that cannot be palpated at the insertion site should be located as soon as possible; if unable to locate implant within the arm, the MHRA recommends using chest imaging. Refer individual with suspected migration as required.Correct subdermal insertion reduces the risk of these events.Insertion or removal of the implant may cause some bruising, including haematoma in some cases, slight local irritation, pain or itching. Other possible complications include nerve damage, and deep or intramuscular insertion.Insertion of the implant may cause vasovagal reactions (such as hypotension, dizziness, or syncope). |
| **Storage** | Medicines must be stored securely according to national guidelines and in accordance with the product SPC |
| **Drug interactions** | Individuals using enzyme-inducing drugs/herbal products or within 28 days of stopping them are excluded from this PGD. Refer to FSRH CEU Guidance: [Drug Interactions with Hormonal Contraception](https://www.fsrh.org/standards-and-guidance/documents/ceu-clinical-guidance-drug-interactions-with-hormonal/) for further detail.All concurrent medications, including those purchased should be considered for interactions.A detailed list of drug interactions is available in the individual product SPC, which is available from the electronic Medicines Compendium website www.medicines.org.uk the BNF [www.bnf.org](http://www.bnf.org) and FSRH CEU Guidance: Drug Interactions with Hormonal Contraception <https://www.fsrh.org/standards-and-guidance/documents/ceu-clinical-guidance-drug-interactions-with-hormonal/> Refer to a prescriber if any concern of a clinically significant drug interaction. |
| **Identification & management of adverse reactions** | A detailed list of adverse reactions is available in the SPC, which is available from the [electronic Medicines Compendium](http://www.medicines.org.uk) and [BNF](http://www.bnf.org) The implant is generally well tolerated. The main reported side effects include:**Common** * Irregular, unpredictable bleeding which includes: amenorrhoea, frequent or prolonged bleeding
* Headache
* Acne
* Breast tenderness and pain

**Less common** * Mood changes
* Reduced libido
* Nausea
* Fluid retention
* Some local scarring

If overdose or severe adverse reaction suspected manage following local policy. |
| **Additional facilities and supplies** | * Access to working telephone
* Suitable waste disposal facilities
* Immediate access to in-date anaphylaxis kit (IM adrenaline 1:1000)
 |
| **Management of and reporting procedure for adverse reactions** | * Healthcare professionals and individuals are encouraged to report suspected adverse reactions to the Medicines and Healthcare products Regulatory Agency (MHRA) using the [Yellow Card reporting scheme](http://yellowcard.mhra.gov.uk/)
* Record all adverse drug reactions (ADRs) in the individual’s medical record.
* Report via organisation incident policy.
 |
| **Written information and further advice to be given to individual**  | * Ensure access to product information prior to insertion or supply of the medicine and especially discuss the side effects and how to report.
* Provide Manufacturer’s Patient Information Leaflet (PIL).
* Explain mode of action, side effects, and benefits of the medicine.
* Advise that limited evidence suggests no increased risk of venous or arterial thromboembolic events associated with use of the implant.
* Advise on need for additional barrier method and pregnancy test as appropriate.
* How to care for the insertion site and advise to return (or where to seek advice) if concerns about insertion site
* Advise that a change in bleeding pattern is likely and provide clear, accessible information about possible bleeding patterns and advise how to access support for management of problematic bleeding and advise to return (or where to seek advice) if they are concerned or if irregular bleeding persists.
* Individuals should be advised that intravascular insertion and distant migration are rare complications of the implant insertion procedure. Advise individual to return (or where to seek advice) if unable to palpate implant, it changes shape or individual develops pain around the site.
* Individuals should be advised that current use of progestogen-only contraceptives is associated with a small increased risk of breast cancer which reduces with time after stopping.
* Give information on who to contact in the event of an adverse reaction or concerns.
* Provide verbal and written information on the implant.
 |
| **Advice/follow up treatment** | Advise individual:* How long the implant lasts for – when they need to arrange for removal and replacement.
* To return to clinic (or where to seek advice) if they have any concerns.
 |
| **Records** | **Record:** The consent of the individual and* If individual is under 13 years of age record action taken
* If individual is under 16 years of age document capacity using Fraser guidelines. If not competent record action taken.
* If individual over 16 years of age and not competent, record action taken
* GP contact details where appropriate
* Attendance date
* Reason for attendance
* Relevant past and present medical and family history, including drug history
* Any known allergy
* Relevant examination findings
* Inclusion or exclusion from PGD
* Advice given about the implant including side effects, benefits, and when and what to do if any concerns
* Details of any adverse drug reactions and what action taken
* Any administration outside the marketing authorisation
* Record the name/brand, dose of the medication, site of insertion (including which arm and exact location), and palpation of implant following procedure by both the nurse and the individual
* Batch number and expiry date of product in line with local procedure
* Record any referral, follow up and/or signposting arrangements
* Any other relevant information that was provided to the individual
* A statement that supply and insertion is by using a PGD
* Name and signature (which may be an electronic signature) of the clinician supplying and administering the medicine

Records should be signed and dated (or a password-controlled e-records) and securely kept for a defined period in line with local policy. All records should be clear, legible and contemporaneous.A record of all individuals receiving treatment under this PGD should also be kept for audit purposes in accordance with local policy. |

**4. Key references**

|  |  |
| --- | --- |
| **Key references (accessed February 2024)** | * Electronic Medicines Compendium <http://www.medicines.org.uk/>
* Electronic BNF <https://bnf.nice.org.uk/>
* NICE Medicines practice guideline “Patient Group Directions” <https://www.nice.org.uk/guidance/mpg2>
* National Institute of Health and Clinical Excellence; Long Acting Reversible Contraception CG30 (2005) Last revised July 2019 <https://www.nice.org.uk/guidance/cg30>
* FSRH Clinical Guideline: Progestogen-only Implant (February 2021) [Progestogen-only Implants | FSRH](https://www.fsrh.org/Public/Standards-and-Guidance/Progestogen-only-Implants.aspx)
* Faculty of Sexual and Reproductive Health Drug Interactions with Hormonal Contraception – May 2022

[FSRH CEU Guidance: Drug Interactions with Hormonal Contraception (May 2022) | FSRH](https://www.fsrh.org/Public/Documents/ceu-clinical-guidance-drug-interactions-with-hormonal.aspx) * Faculty of Sexual and Reproductive Healthcare (2016) UK Medical Eligibility Criteria for Contraceptive Use.

[UK Medical Eligibility Criteria for Contraceptive Use (UKMEC) | FSRH](https://www.fsrh.org/Public/Public/Standards-and-Guidance/uk-medical-eligibility-criteria-for-contraceptive-use-ukmec.aspx?hkey=82727ce6-756b-4b88-a5ab-acaf27c48669) * Faculty of Sexual and Reproductive Healthcare Clinical Guideline: Quick Starting Contraception (April 2017)

[FSRH Clinical Guideline: Quick Starting Contraception (April 2017) | FSRH](https://www.fsrh.org/Public/Documents/fsrh-clinical-guidance-quick-starting-contraception-april-2017.aspx)* FSRH Clinical Guideline: Problematic Bleeding with Hormonal Contraception (July 2015) [FSRH Clinical Guideline: Problematic Bleeding with Hormonal Contraception (July 2015) | FSRH](https://www.fsrh.org/Public/Documents/ceu-guidance-problematic-bleeding-hormonal-contraception.aspx?WebsiteKey=f858b086-d221-4a83-9688-824162920b1b)
* Faculty of Sexual and Reproductive Healthcare (2014) Contraceptive choices for women with cardiac disease [FSRH Clinical Guideline: Contraceptive Choices for Women with Cardiac Disease (June 2014) | FSRH](https://www.fsrh.org/Public/Documents/ceu-guidance-contraceptive-choices-for-women-with-cardiac-disease.aspx)
* Faculty of Sexual and Reproductive Healthcare (2017) Amended October 2020 Contraception After Pregnancy [Contraception After Pregnancy | FSRH](https://www.fsrh.org/Public/Standards-and-Guidance/Contraception-After-Pregnancy.aspx)
* Faculty of Sexual and Reproductive Healthcare (2023)

Response to new study on use of combined and progestogen-only hormonal contraception and breast cancer risk.[FSRH response to new study on use of CHC and POC and breast cancer risk (March 2023) | FSRH](https://www.fsrh.org/Public/Documents/response-to-study-on-use-of-chc-and-poc-and-breast-cancer.aspx)* Medicines and Healthcare Regulatory Agency (2016)

Nexplanon (etonogestrel) contraceptive implants: reports of device in vasculature and lung[Nexplanon (etonogestrel) contraceptive implants: reports of device in vasculature and lung - GOV.UK (www.gov.uk)](https://www.gov.uk/drug-safety-update/nexplanon-etonogestrel-contraceptive-implants-reports-of-device-in-vasculature-and-lung) |

 **Appendix A - Registered health professional authorisation sheet (example – local versions/electronic systems may be used)**

**PGD Name/Version Valid from: Expiry:**

Before signing this PGD, check that the document has had the necessary authorisations. Without these, this PGD is not lawfully valid.

**Registered health professional**

By signing this patient group direction you are indicating that you agree to its contents and that you will work within it.

Patient group directions do not remove inherent professional obligations or accountability.

It is the responsibility of each professional to practise only within the bounds of their own competence and professional code of conduct.

|  |
| --- |
| **I confirm that I have read and understood the content of this Patient Group Direction and that I am willing and competent to work to it within my professional code of conduct.** |
| **Name** | **Designation** | **Signature** | **Date** |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |

**Authorising manager**

|  |
| --- |
| **I confirm that the registered health professionals named above have declared themselves suitably trained and competent to work under this PGD. I give authorisation on behalf of insert name of organisation for the above named health care professionals who have signed the PGD to work under it.** |
| **Name** | **Designation** | **Signature** | **Date** |
|  |  |  |  |

**Note to authorising manager**

Score through unused rows in the list of registered health professionals to prevent additions post managerial authorisation.

This authorisation sheet should be retained to serve as a record of those registered health professionals authorised to work under this PGD.

Add details on how this information is to be retained according to organisation PGD policy.